Open-sourcing data and annotations for renal cell carcinoma yielded 142 annotated CT scans from 101 patients
Open-source CT scans aim to boost kidney cancer AI research
This cohort study involved 101 patients with renal cell carcinoma (RCC) and analyzed 142 annotated CT scans.
Researchers release 142 annotated CT scans from 101 kidney cancer patients to accelerate AI development.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Office-based holmium-YAG TULA shows feasibility and safety for recurrent NMIBC in a high-risk cohort
Laser Treatment for Bladder Cancer Now Done in Office
This retrospective cohort study evaluated 53 patients undergoing their first office-based transurethral laser ablation (TULA) for recurrent …
Men with small, recurring bladder tumors can now get laser treatment in an office instead of surgery, avoiding hospital stays and general an…
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
Low Drug Levels Mean Worse Outcomes
This randomized phase 2 trial evaluated nivolumab and ipilimumab trough plasma concentrations in 110 patients with metastatic clear cell ren…
Low levels of a common kidney cancer drug are linked to worse survival outcomes when used with another powerful medicine.
Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
Hope for Bladder Cancer When Chemo Isn't an Option
This Phase II trial evaluated neoadjuvant nivolumab alone or with ipilimumab in 30 cisplatin-ineligible patients with muscle-invasive bladde…
Patients with advanced bladder cancer who can't take standard chemo may now qualify for surgery after a new immunotherapy treatment.
Targeted therapy versus non-targeted therapy in renal cell carcinoma patients
Real-world study in Taiwan shows targeted therapy offers similar life expectancy for advanced kidney cancer compared to non-targeted therapy
This real-world cohort study analyzed 14,131 renal cell carcinoma cases in Taiwan from 1998 to 2016.
In Taiwan, targeted therapy for advanced kidney cancer offers similar life expectancy to non-targeted therapy, with both groups living aroun…
Simlukafusp alfa plus atezolizumab with or without bevacizumab shows antitumor activity in metastatic renal cell carcinoma
Does adding bevacizumab nearly triple the time before kidney cancer grows back?
A phase Ib randomized open-label study in 66 patients with metastatic renal cell carcinoma found objective response rates of 25% with simluk…
Adding bevacizumab nearly tripled the time before kidney cancer grew back compared to a two-drug mix in this early study.
Predictors of pathological upstaging in clinical stage T1 renal cell carcinoma include male gender, age, and irregular margins
Could your kidney tumor look smaller than it really is inside?
This meta-analysis and systematic review evaluated 24,957 patients with clinical stage T1 renal cell carcinoma to identify predictors of pat…
A kidney tumor that looks small on a scan might actually be more advanced than doctors think, raising the risk of it returning after surgery…